BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Meridian Bioscience Eliminates Cold Chain with the First Liquid Ambient Temperature Stable qPCR Master Mixes

  September 17, 2025

   · 

  4 min read
• Press Releases

  Virtual SOHO Breakthroughs in Blood Cancers meeting launches November 20, 2025

  September 17, 2025

   · 

  1 min read
• 

  China

  Choosing China: Akeso’s $3M Beginnings and the Rise of China’s Biotech Sector

  From a small team of researchers and skipped salaries, CEO Michelle Xia has steered Akeso to become one of the most exciting companies in the industry today.

  September 17, 2025

   · 

  8 min read

   · 

  Tristan Manalac
• Press Releases

  Quetzal Therapeutics Appoints Dr. Shaad Abedin as Chief Medical Officer

  September 17, 2025

   · 

  2 min read
• Press Releases

  UTR Therapeutics Publishes Landmark Preclinical Data in Frontiers in Pharmacology Supporting IND Submission for First-in-Class c-MYC RNA Therapeutic

  September 17, 2025

   · 

  3 min read
• Press Releases

  ZKR Orthopedics Announces First Patella LIFT™ Surgeries on the East Coast at Hospital for Special Surgery in Enrollment of FDA PELICAN Trial

  September 17, 2025

   · 

  2 min read
• 

  Editorial

  Serena Williams Hawks GLP-1s for Ro Even as Pharmas Face Tightening Oversight

  The FDA has vowed to fix a pharma ad loophole—but they’re targeting the wrong one.

  September 17, 2025

   · 

  3 min read

   · 

  Annalee Armstrong
• Press Releases

  AABB’s Cell and Gene Therapy Standards for Pharmacy, First Edition, Takes Effect October 1

  September 17, 2025

   · 

  1 min read
• 

  FDA

  In New DTC Ad Crackdown, FDA Trying To Close a Loophole That Isn’t

  While the FDA is trumpeting this new initiative as “sweeping reforms” to the way drug companies can advertise, experts say the regulator is going after a problem that doesn’t exist.

  September 17, 2025

   · 

  7 min read

   · 

  Annalee Armstrong
• 

  Startups

  Ollin Emerges From Stealth With $100M To Develop Eye Disease Bispecifics

  OLN324 targets both VEGF and Ang2, the same mechanism of action as Roche’s Vabysmo, the Swiss giant’s multi-blockbuster treatment for wet macular degeneration and diabetic macular edema.

  September 17, 2025

   · 

  2 min read

   · 

  Tristan Manalac